I am a dermatologist. Make a best comphrehensive, detailed note of topic corticosteroids . Use above attached source. Also add from Fitzpatrick, Andrew’s, Rooks, Bologna’s and other relevant sources. Also add recent advances.and provide me a pdf
Reading File
Reading File
general-purpose
You are a medical research assistant. Extract comprehensive information about CORTICOSTEROIDS from two PDF files. PDF 1: /home/daytona/workspace/attachments/d8f098c0-5779-4a14-a5ba-49c3cf5c9833/wolvertonComprehensive Dermatologic Drug Therapy 3ed.pdf PDF 2: /home/daytona/workspace/attachments/d8f098c0-5779-4a14-a5ba-49c3cf5c9833/Topical Steroids.pdf Instructions: 1. First read the PDF skill at /home/daytona/skills/pdf/SKILL.md to understand how to extract text 2. Use Python/pdfplumber or pypdf to extract text from both PDFs - focus on ALL corticosteroid-related chapters/sections 3. From Wolverton: Find chapters on systemic corticosteroids AND topical corticosteroids. Extract ALL text including: pharmacology, mechanism of action, pharmacokinetics, classification/potency, indications, dosing regimens, adverse effects, monitoring, drug interactions, contraindications, special populations (pregnancy, pediatrics, elderly), alternate-day therapy, pulse therapy, intravenous steroids 4. From Topical Steroids PDF: Extract everything - classification, potency ranking, vehicle types, application techniques, side effects, specific indications, occlusion, compounding, tachyphylaxis Return a structured, detailed summary with ALL key clinical information, tables, dosing details, and drug lists. Be thorough - this is for a comprehensive dermatology reference note. Return as much detail as possible.
general-purpose
You are a medical librarian assistant. Query the medical textbook library database to find ALL information about CORTICOSTEROIDS in dermatology textbooks (Fitzpatrick's Dermatology, Andrews' Diseases of the Skin, Rook's Textbook of Dermatology, Bologna's Dermatology, and any other dermatology textbooks available). Use the query_library_db tool with these SQL queries: 1. First find available books: SELECT isbn, title, speciality FROM v_book_overview ORDER BY title LIMIT 20 2. Search headings for corticosteroids: SELECT title, book_title, '/textbooks/' || block_file_path AS file_path, line_number, para_line_ranges, para_count FROM headings_fts WHERE headings_fts MATCH 'corticosteroid' ORDER BY rank LIMIT 15 3. Search headings for topical steroids: SELECT title, book_title, '/textbooks/' || block_file_path AS file_path, line_number, para_line_ranges, para_count FROM headings_fts WHERE headings_fts MATCH 'topical corticosteroid' ORDER BY rank LIMIT 10 4. Search paragraphs for systemic corticosteroids: SELECT book_title, section_heading, '/textbooks/' || block_file_path AS file_path, line_start, line_end, snippet(paragraphs_fts, 0, '>>>', '<<<', '...', 50) as snippet FROM paragraphs_fts WHERE paragraphs_fts MATCH '"systemic corticosteroid" AND dermatology' ORDER BY rank LIMIT 10 5. Search for steroid potency classification: SELECT book_title, section_heading, '/textbooks/' || block_file_path AS file_path, line_start, line_end, snippet(paragraphs_fts, 0, '>>>', '<<<', '...', 50) as snippet FROM paragraphs_fts WHERE paragraphs_fts MATCH '"steroid potency" OR "topical steroid" AND classification' ORDER BY rank LIMIT 10 After finding relevant file paths and line numbers, use read_file to read the actual content from each relevant block file (read 200+ lines at a time using offset/limit). Extract ALL content about: - Classification and potency ranking of corticosteroids - Mechanism of action - Pharmacokinetics - Indications in dermatology - Adverse effects (local and systemic) - Monitoring parameters - Special considerations - Intralesional corticosteroids - Systemic corticosteroids Return comprehensive extracted text organized by source (book name). Include as much detail as possible.
Searching PubMed
topical corticosteroids dermatology advances
Reading File
Finding Sources
Finding Sources
Finding Sources
Running Command
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Running Command
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Running Command
Running Command
Reading File
Reading File
Reading File
Running Command
Finding Sources
Finding Sources
Running Command
Running Command
Reading File
Reading File
Running Command
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Running Command
Running Command
Searching PubMed
topical corticosteroid adverse effects safety new formulations
Searching PubMed
glucocorticoid receptor selective agonist dissociated steroid dermatology
Searching PubMed
roflumilast tapinarof corticosteroid sparing atopic dermatitis psoriasis
Searching PubMed
halobetasol lotion foam new formulation lichen sclerosus plaque psoriasis
Searching PubMed
topical corticosteroid phobia adherence atopic dermatitis treatment outcomes
Searching the Web
recent advances topical corticosteroids dermatology 2023 2024 new formulations SEGRA dissociated steroids
Reading Web Page
recent advances topical corticosteroids new formulations steroid sparing agents SEGRA nonsteroidal
Running Command
Give me pdf
Running Command
Give me in chat
Quiz from the topic
Here is a comprehensive quiz on Corticosteroids in Dermatology — covering all major subtopics. Answers are at the end.
🧪 CORTICOSTEROIDS IN DERMATOLOGY — QUIZ
SECTION A: PHARMACOLOGY & MECHANISM
1. The vasoconstriction assay for ranking topical corticosteroid (TCS) potency was first described by:
- a) Sulzberger and Witten
- b) Stoughton
- c) McKenzie and Stoughton
- d) Johnson and Lazarus
2. Which structural modification converts betamethasone into clobetasol propionate?
- a) Addition of acetonide group at C16,C17
- b) Replacement of C21-OH with chlorine
- c) Esterification at C17
- d) Double bond at C1
3. The primary mechanism by which glucocorticoids inhibit prostaglandin and leukotriene synthesis is through induction of:
- a) Cyclooxygenase-2
- b) NF-κB
- c) Lipocortin (Annexin A1) → inhibiting phospholipase A₂
- d) IL-2 receptor
4. Which of the following is an INACTIVE prodrug requiring hepatic conversion to become active?
- a) Prednisolone
- b) Methylprednisolone
- c) Prednisone
- d) Betamethasone
5. Cortisol has a plasma half-life of approximately:
- a) 30 minutes
- b) 60 minutes
- c) 90 minutes
- d) 180 minutes
6. Approximately what percentage of daily cortisol is produced between 4 AM and 10 AM?
- a) 25%
- b) 50%
- c) 75%
- d) 90%
7. Which intracellular chaperone protein complexes with the glucocorticoid receptor before ligand binding?
- a) FKBP52
- b) HSP70
- c) HSP90
- d) Cyclophilin
SECTION B: POTENCY CLASSIFICATION & VEHICLES
8. According to the US 7-class system, which class is clobetasol propionate 0.05%?
- a) Class II
- b) Class I
- c) Class III
- d) Class IV
9. The same corticosteroid molecule in ointment form is generally _______ potent than in cream form:
- a) Less
- b) Equally
- c) More
- d) Depends entirely on concentration
10. Which vehicle is MOST appropriate for a weeping, moist, intertriginous dermatitis?
- a) Ointment
- b) Gel
- c) Cream
- d) Tape
11. Occlusion increases percutaneous absorption of topical corticosteroids by approximately:
- a) 2-5 times
- b) 5-10 times
- c) 10-100 times
- d) 100-500 times
12. Regional penetration is GREATEST at which body site?
- a) Forearm
- b) Scalp
- c) Scrotum and eyelids
- d) Palms
13. Which of the following TCS does NOT contain propylene glycol and is a superpotent agent?
- a) Mometasone furoate cream
- b) Clobetasol propionate (scalp application, Temovate)
- c) Fluocinonide cream
- d) Triamcinolone acetonide 0.1% cream
14. A "fingertip unit" (FTU) in an adult male weighs approximately:
- a) 0.2 g
- b) 0.49 g
- c) 1.0 g
- d) 2.0 g
SECTION C: PHARMACOKINETICS OF SYSTEMIC CORTICOSTEROIDS
15. Which systemic corticosteroid has the LONGEST biological half-life?
- a) Prednisone
- b) Methylprednisolone
- c) Triamcinolone
- d) Dexamethasone
16. Equivalent anti-inflammatory dose of dexamethasone is:
- a) 5 mg
- b) 0.75 mg
- c) 4 mg
- d) 25 mg
17. In severe hepatic disease, which oral agent should be PREFERRED over prednisone?
- a) Methylprednisolone
- b) Prednisolone
- c) Triamcinolone
- d) Dexamethasone
18. Which of the following has the HIGHEST mineralocorticoid potency?
- a) Dexamethasone
- b) Betamethasone
- c) Fludrocortisone
- d) Triamcinolone
SECTION D: INDICATIONS
19. Which of the following dermatoses is considered HIGHLY responsive to topical corticosteroids?
- a) Granuloma annulare
- b) Palmoplantar psoriasis
- c) Seborrheic dermatitis
- d) Lichen planus
20. Topical corticosteroids are considered FIRST-LINE therapy for which of the following?
- a) Rosacea
- b) Atopic dermatitis
- c) Tinea corporis
- d) Molluscum contagiosum
21. For oral/genital erosions in Behçet's disease, the recommended application frequency of high-potency TCS is:
- a) Once daily
- b) Twice daily
- c) Four times daily (QID)
- d) Once weekly
22. The combination of fluocinolone acetonide 0.01% + hydroquinone 4% + tretinoin 0.05% is used for:
- a) Vitiligo
- b) Melasma
- c) Discoid lupus
- d) Morphea
23. Clobetasol propionate has been shown in a landmark RCT to be equivalent to oral prednisone for which condition?
- a) Pemphigus vulgaris
- b) Bullous pemphigoid
- c) Linear IgA disease
- d) Dermatitis herpetiformis
24. For patch-stage cutaneous T-cell lymphoma (CTCL), which TCS potency class is considered most effective?
- a) Class VI (mild)
- b) Class IV (intermediate)
- c) Class I (superpotent/ultrapotent)
- d) Class V (lower intermediate)
SECTION E: ADVERSE EFFECTS
25. Which adverse effect of topical corticosteroids is IRREVERSIBLE?
- a) Epidermal atrophy
- b) Telangiectasias
- c) Striae distensae
- d) Hypopigmentation
26. Tachyphylaxis to topical corticosteroids is typically demonstrable by which day of continuous application?
- a) Day 1
- b) Day 4
- c) Day 14
- d) Day 28
27. The recommended "safe upper limit" for superpotent TCS (Class I) per week to avoid HPA suppression is:
- a) <20 g/week
- b) <50 g/week
- c) <100 g/week
- d) <200 g/week
28. Which screening test is used as the PRIMARY test for HPA axis suppression from TCS?
- a) 24-hour urinary cortisol
- b) 8 AM plasma cortisol
- c) Dexamethasone suppression test
- d) Random serum cortisol
29. Granuloma gluteale infantum is a recognized side effect of:
- a) Using anti-fungal creams in the diaper area
- b) Using potent TCS for diaper dermatitis
- c) Systemic prednisone in neonates
- d) Intralesional triamcinolone in infants
30. The prevalence of allergic contact dermatitis (ACD) to corticosteroids is approximately:
- a) <1%
- b) 2-3%
- c) ~5%
- d) ~15%
31. Which of the following is the BEST patch-test screening marker for Group A corticosteroid allergy?
- a) Budesonide
- b) Tixocortol pivalate
- c) Hydrocortisone-17-butyrate
- d) Clobetasol-17-propionate
32. Steroid rosacea on the face is caused by:
- a) Vasoconstriction effect of TCS
- b) Antimicrobial effect of TCS
- c) Chronic TCS use with rebound erythema/pustules on withdrawal
- d) Allergic contact dermatitis to TCS
33. Osteoporosis occurs in what percentage of long-term systemic corticosteroid users (without preventive measures)?
- a) 10-15%
- b) 20-25%
- c) 30-50%
- d) 60-70%
34. Even a dose as low as _______ mg/day of prednisone has adverse effects on bone:
- a) 10 mg
- b) 7.5 mg
- c) 5 mg
- d) 2.5 mg
35. The psychiatric complication of steroid psychosis is most commonly seen at prednisone doses exceeding:
- a) 20 mg/day
- b) 40 mg/day
- c) 60 mg/day
- d) 80 mg/day
SECTION F: SPECIAL POPULATIONS & MONITORING
36. Regarding TCS use in pregnancy, which statement is MOST accurate?
- a) Potent TCS are safe in all trimesters
- b) Mild/moderate TCS are preferred; potent TCS are associated with fetal growth retardation
- c) All TCS are absolutely contraindicated in pregnancy
- d) Superpotent TCS are associated with orofacial cleft
37. Why are infants at higher risk for systemic absorption of TCS compared to adults?
- a) Thicker stratum corneum
- b) Higher body surface area to body weight ratio and thinner skin
- c) Higher expression of glucocorticoid receptors
- d) Increased keratinocyte turnover
38. According to Bologna's tapering guidelines, when the prednisone dose is between 5-10 mg/day, the taper rate should be:
- a) 5 mg per week
- b) 2.5 mg per week
- c) 1 mg every 2-3 weeks
- d) 5 mg every 2 weeks
39. Calcium and Vitamin D supplementation should be started in ALL patients expected to use systemic GC for at least:
- a) 1 week
- b) 2 weeks
- c) 3 months
- d) 6 months
40. Live vaccines are considered safe with systemic corticosteroids only at doses:
- a) < 5 mg/day at any duration
- b) < 10 mg/day
- c) < 20 mg/day (any duration) OR < 2 weeks at any dose
- d) They are never safe with systemic corticosteroids
SECTION G: INTRALESIONAL & SYSTEMIC USE
41. For keloids, the initial intralesional triamcinolone acetonide concentration used is:
- a) 2-5 mg/mL
- b) 5-10 mg/mL
- c) 10-20 mg/mL
- d) 20-40 mg/mL
42. The recommended monthly limit for intralesional triamcinolone acetonide (Kenalog) to avoid HPA suppression is:
- a) 10 mg
- b) 20 mg
- c) 40 mg
- d) 80 mg
43. For IV pulse methylprednisolone therapy, what is the standard dose range per pulse?
- a) 100-250 mg over 30 min
- b) 250-500 mg over 1 hour
- c) 500 mg to 1 g over 2 hours
- d) 2-4 g over 4 hours
44. Intramuscular long-acting triamcinolone acetonide should be given no more than:
- a) 2 times per year
- b) 4-6 times per year
- c) Monthly
- d) Weekly
45. Which formulation of triamcinolone should be used for CUTANEOUS intralesional injections (NOT joint injections)?
- a) Triamcinolone hexacetonide
- b) Triamcinolone diacetate
- c) Triamcinolone acetonide
- d) Triamcinolone benetonide
SECTION H: CROSS-REACTIVITY & ACD
46. A patient develops ACD to budesonide. Which cross-reactivity group does budesonide belong to, and which other groups does it cross-react with?
- a) Group A; cross-reacts with C
- b) Group B; cross-reacts with D2
- c) Group D1; cross-reacts with A
- d) Group C; cross-reacts with B
47. A patient is allergic to hydrocortisone (Group A). Which TCS should you AVOID as a substitute?
- a) Betamethasone dipropionate (Group D1)
- b) Methylprednisolone aceponate (Group D2) — as it metabolizes to methylprednisolone (Group A)
- c) Halcinonide (Group B)
- d) Fluticasone propionate (Group D1)
48. The two most common allergens found in TCS VEHICLES are:
- a) Parabens and benzyl alcohol
- b) Propylene glycol and sorbitan sesquioleate
- c) Cetyl alcohol and polysorbate 80
- d) Lanolin and mineral oil
SECTION I: PRACTICAL PEARLS & RECENT ADVANCES
49. The "soak and smear" technique improves TCS penetration because:
- a) It removes scale and allows direct drug contact
- b) Hydration of the stratum corneum increases TCS absorption up to 5-fold
- c) Warm water increases blood flow and systemic absorption
- d) It activates glucocorticoid receptors in the epidermis
50. The optimal time for TCS application to maximize vasoconstrictive effect is:
- a) Early morning (6-8 AM)
- b) Midday
- c) Late afternoon
- d) Bedtime
51. Which of the following represents a newer steroid-SPARING topical alternative approved post-2020?
- a) Pimecrolimus cream
- b) Tacrolimus ointment
- c) Ruxolitinib cream 1.5% (JAK1/2 inhibitor)
- d) Adapalene gel
52. Roflumilast cream/foam works by inhibiting:
- a) JAK1/2
- b) AhR (aryl hydrocarbon receptor)
- c) PDE4 (phosphodiesterase-4)
- d) IL-31 receptor
53. Topical steroid withdrawal (TSW) is most commonly reported following:
- a) Short-term use of Class VII TCS
- b) Prolonged use of potent/superpotent TCS especially on the face and genitalia
- c) Intralesional triamcinolone use
- d) Alternate-day systemic prednisolone
54. Which TCS has uniquely low systemic bioavailability due to rapid hepatic first-pass metabolism, making it preferred for long-term use especially in children?
- a) Clobetasol propionate
- b) Triamcinolone acetonide
- c) Mometasone furoate and fluticasone propionate
- d) Betamethasone dipropionate
55. Poststeroid panniculitis is most commonly seen in:
- a) Adults after prolonged low-dose steroids
- b) Children after high-dose systemic corticosteroids and rapid withdrawal
- c) Elderly patients after intralesional injections
- d) Neonates after topical TCS in the diaper area
✅ ANSWER KEY
| Q | Answer | Key Point |
|---|---|---|
| 1 | c | McKenzie and Stoughton described the vasoconstriction assay |
| 2 | b | C21-OH replaced by Cl → clobetasol (↑↑ potency) |
| 3 | c | Lipocortin/Annexin A1 → inhibits phospholipase A₂ |
| 4 | c | Prednisone (C11 ketone) requires hepatic 11-hydroxylation to prednisolone |
| 5 | c | Cortisol plasma T½ = 90 minutes |
| 6 | c | ~75% produced 4 AM-10 AM (circadian rhythm) |
| 7 | c | HSP90 complexes with GCR before ligand binding; FKBP51 also involved |
| 8 | b | Clobetasol propionate = Class I (superpotent) |
| 9 | c | Ointment > cream > lotion in potency (same molecule) |
| 10 | c | Cream — for moist/intertriginous/exudative areas |
| 11 | c | Occlusion ↑ absorption 10-100 times |
| 12 | c | Scrotum and eyelids = highest penetration (36-40× palms/soles) |
| 13 | b | Clobetasol scalp application (Temovate) — no propylene glycol |
| 14 | b | Adult male FTU ≈ 0.49 g |
| 15 | d | Dexamethasone biological T½ = 36-54 hours |
| 16 | b | Dexamethasone equivalent dose = 0.75 mg |
| 17 | b | Prednisolone (already active; no hepatic conversion needed) |
| 18 | c | Fludrocortisone — mineralocorticoid potency 250× cortisol |
| 19 | c | Seborrheic dermatitis is highly TCS-responsive |
| 20 | b | Atopic dermatitis — TCS are first-line pharmacologic therapy |
| 21 | c | QID (4 times daily) for Behçet's oral/genital erosions |
| 22 | b | Triluma (fluocinolone + hydroquinone + tretinoin) = melasma |
| 23 | b | Bullous pemphigoid — clobetasol 0.05% cream = oral prednisone (n=341 RCT) |
| 24 | c | Class I ultrapotent TCS most effective for patch-stage CTCL |
| 25 | c | Striae distensae are IRREVERSIBLE |
| 26 | b | Tachyphylaxis demonstrable by day 4 |
| 27 | b | <50 g/week for Class I superpotent TCS |
| 28 | b | 8 AM plasma cortisol = primary screening test |
| 29 | b | Potent TCS in diaper area → granuloma gluteale infantum |
| 30 | c | ~5% incidence (NACDG 2005) |
| 31 | b | Tixocortol pivalate = Group A screening marker |
| 32 | c | Chronic TCS use → rebound pustular eruption = steroid rosacea |
| 33 | c | 30-50% of chronically treated patients (without prevention) |
| 34 | d | Even 2.5 mg/day prednisone adversely affects bone |
| 35 | d | Prednisone >80 mg/day → ↑ risk of steroid psychosis |
| 36 | b | Mild/moderate TCS preferred; potent TCS → fetal growth retardation |
| 37 | b | Higher BSA:body weight ratio + thinner skin |
| 38 | c | 5-10 mg/day range → taper by 1 mg every 2-3 weeks |
| 39 | c | ≥3 months of systemic GC → start Ca + Vit D |
| 40 | c | <20 mg/day (any duration) OR <2 weeks at any dose |
| 41 | d | Keloids initially: 20-40 mg/mL triamcinolone acetonide |
| 42 | b | 20 mg/month total intralesional Kenalog limit |
| 43 | c | 500 mg-1 g methylprednisolone over 2 hours |
| 44 | b | IM long-acting TA: max 4-6 times per year |
| 45 | c | Triamcinolone ACETONIDE for cutaneous injections (not hexacetonide) |
| 46 | b | Budesonide = Group B; cross-reacts with D2 |
| 47 | b | Methylprednisolone aceponate (D2) metabolizes to methylprednisolone (A) → avoid in Group A allergy |
| 48 | b | Propylene glycol and sorbitan sesquioleate |
| 49 | b | Stratum corneum hydration ↑ penetration up to 5-fold |
| 50 | c | Late afternoon — endogenous cortisol at minimum; peak TCS vasoconstriction ~6h post-application |
| 51 | c | Ruxolitinib cream (JAK1/2 inhibitor) — approved 2022 for AD and vitiligo |
| 52 | c | Roflumilast = PDE4 inhibitor |
| 53 | b | TSW: prolonged potent/superpotent TCS on face/genitalia |
| 54 | c | Mometasone furoate and fluticasone propionate — rapid hepatic first-pass metabolism |
| 55 | b | Poststeroid panniculitis: children after high-dose GC + rapid withdrawal |
Scoring:
- 50-55 correct: Expert level
- 42-49 correct: Advanced
- 30-41 correct: Proficient
- <30: Review the topic
Sources: Wolverton's Comprehensive Dermatologic Drug Therapy 3e, Fitzpatrick's Dermatology, Andrews' Diseases of the Skin, Bolognia's Dermatology 5e, PMC11903052
Answer key on side
Here is the quiz with the answer key displayed side-by-side with each question.
🧪 CORTICOSTEROIDS IN DERMATOLOGY — QUIZ
SECTION A: PHARMACOLOGY & MECHANISM
| # | Question | Options | ✅ Answer |
|---|---|---|---|
| 1 | The vasoconstriction assay for ranking TCS potency was first described by: | a) Sulzberger and Witten b) Stoughton c) McKenzie and Stoughton d) Johnson and Lazarus | c) McKenzie and Stoughton |
| 2 | Which structural modification converts betamethasone into clobetasol propionate? | a) Addition of acetonide group at C16,C17 b) Replacement of C21-OH with chlorine c) Esterification at C17 d) Double bond at C1 | b) Replacement of C21-OH with chlorine |
| 3 | The primary mechanism by which glucocorticoids inhibit prostaglandin and leukotriene synthesis is through induction of: | a) Cyclooxygenase-2 b) NF-κB c) Lipocortin (Annexin A1) → inhibiting phospholipase A₂ d) IL-2 receptor | c) Lipocortin → inhibits phospholipase A₂ |
| 4 | Which is an INACTIVE prodrug requiring hepatic conversion to become active? | a) Prednisolone b) Methylprednisolone c) Prednisone d) Betamethasone | c) Prednisone (C11 ketone → requires 11-hydroxylation) |
| 5 | Cortisol has a plasma half-life of approximately: | a) 30 min b) 60 min c) 90 min d) 180 min | c) 90 minutes |
| 6 | Approximately what % of daily cortisol is produced between 4 AM and 10 AM? | a) 25% b) 50% c) 75% d) 90% | c) ~75% |
| 7 | Which chaperone protein complexes with the glucocorticoid receptor BEFORE ligand binding? | a) FKBP52 b) HSP70 c) HSP90 d) Cyclophilin | c) HSP90 |
SECTION B: POTENCY CLASSIFICATION & VEHICLES
| # | Question | Options | ✅ Answer |
|---|---|---|---|
| 8 | Clobetasol propionate 0.05% belongs to which US potency class? | a) Class II b) Class I c) Class III d) Class IV | b) Class I (Superpotent) |
| 9 | The same corticosteroid molecule in ointment form is generally _______ than in cream: | a) Less potent b) Equally potent c) More potent d) Depends on concentration only | c) More potent |
| 10 | Best vehicle for a weeping, moist, intertriginous dermatitis: | a) Ointment b) Gel c) Cream d) Tape | c) Cream |
| 11 | Occlusion increases percutaneous absorption by approximately: | a) 2-5× b) 5-10× c) 10-100× d) 100-500× | c) 10-100 times |
| 12 | Regional penetration is GREATEST at which site? | a) Forearm b) Scalp c) Scrotum and eyelids d) Palms | c) Scrotum and eyelids (36-40× palms/soles) |
| 13 | Which superpotent TCS contains NO propylene glycol? | a) Mometasone furoate cream b) Clobetasol propionate scalp application (Temovate) c) Fluocinonide cream d) Triamcinolone 0.1% cream | b) Clobetasol scalp application (Temovate) |
| 14 | A fingertip unit (FTU) in an adult male weighs approximately: | a) 0.2 g b) 0.49 g c) 1.0 g d) 2.0 g | b) 0.49 g |
SECTION C: SYSTEMIC CORTICOSTEROID PHARMACOKINETICS
| # | Question | Options | ✅ Answer |
|---|---|---|---|
| 15 | Which systemic corticosteroid has the LONGEST biological half-life? | a) Prednisone b) Methylprednisolone c) Triamcinolone d) Dexamethasone | d) Dexamethasone (36-54 hours) |
| 16 | Equivalent anti-inflammatory dose of dexamethasone is: | a) 5 mg b) 0.75 mg c) 4 mg d) 25 mg | b) 0.75 mg |
| 17 | In severe hepatic disease, which agent should be PREFERRED over prednisone? | a) Methylprednisolone b) Prednisolone c) Triamcinolone d) Dexamethasone | b) Prednisolone (already active; no hepatic conversion needed) |
| 18 | Which has the HIGHEST mineralocorticoid potency? | a) Dexamethasone b) Betamethasone c) Fludrocortisone d) Triamcinolone | c) Fludrocortisone (250× cortisol) |
SECTION D: INDICATIONS
| # | Question | Options | ✅ Answer |
|---|---|---|---|
| 19 | Which dermatosis is considered HIGHLY responsive to TCS? | a) Granuloma annulare b) Palmoplantar psoriasis c) Seborrheic dermatitis d) Lichen planus | c) Seborrheic dermatitis |
| 20 | TCS are FIRST-LINE therapy for: | a) Rosacea b) Atopic dermatitis c) Tinea corporis d) Molluscum contagiosum | b) Atopic dermatitis |
| 21 | For oral/genital erosions in Behçet's disease, recommended TCS application frequency: | a) Once daily b) Twice daily c) Four times daily (QID) d) Once weekly | c) QID × 1-2 weeks |
| 22 | Triluma (fluocinolone acetonide 0.01% + hydroquinone 4% + tretinoin 0.05%) is used for: | a) Vitiligo b) Melasma c) Discoid lupus d) Morphea | b) Melasma |
| 23 | Clobetasol propionate cream was shown equivalent to oral prednisone in a landmark RCT for: | a) Pemphigus vulgaris b) Bullous pemphigoid c) Linear IgA disease d) Dermatitis herpetiformis | b) Bullous pemphigoid (n=341 RCT) |
| 24 | For patch-stage CTCL, which TCS potency class is most effective? | a) Class VI (mild) b) Class IV (intermediate) c) Class I (superpotent) d) Class V | c) Class I (superpotent/ultrapotent) |
SECTION E: ADVERSE EFFECTS
| # | Question | Options | ✅ Answer |
|---|---|---|---|
| 25 | Which adverse effect of TCS is IRREVERSIBLE? | a) Epidermal atrophy b) Telangiectasias c) Striae distensae d) Hypopigmentation | c) Striae distensae |
| 26 | Tachyphylaxis to TCS is typically demonstrable by which day? | a) Day 1 b) Day 4 c) Day 14 d) Day 28 | b) Day 4 |
| 27 | Safe upper weekly limit for Class I superpotent TCS: | a) <20 g/week b) <50 g/week c) <100 g/week d) <200 g/week | b) <50 g/week |
| 28 | Primary screening test for HPA axis suppression: | a) 24-hour urinary cortisol b) 8 AM plasma cortisol c) Dexamethasone suppression test d) Random serum cortisol | b) 8 AM plasma cortisol |
| 29 | Granuloma gluteale infantum results from: | a) Antifungal creams in diaper area b) Potent TCS for diaper dermatitis c) Systemic prednisone in neonates d) Intralesional TA in infants | b) Potent TCS in the diaper area |
| 30 | Prevalence of ACD to corticosteroids is approximately: | a) <1% b) 2-3% c) ~5% d) ~15% | c) ~5% (NACDG 2005) |
| 31 | Best patch-test screening marker for Group A TCS allergy: | a) Budesonide b) Tixocortol pivalate c) Hydrocortisone-17-butyrate d) Clobetasol-17-propionate | b) Tixocortol pivalate |
| 32 | Steroid rosacea is caused by: | a) Vasoconstriction effect b) Antimicrobial effect c) Chronic TCS use with rebound on withdrawal d) ACD to TCS | c) Chronic use → rebound erythema/pustules on withdrawal |
| 33 | Osteoporosis occurs in what % of long-term GC users without prevention? | a) 10-15% b) 20-25% c) 30-50% d) 60-70% | c) 30-50% |
| 34 | Even _____ mg/day prednisone adversely affects bone: | a) 10 mg b) 7.5 mg c) 5 mg d) 2.5 mg | d) 2.5 mg/day |
| 35 | Steroid psychosis risk increases most at prednisone doses exceeding: | a) 20 mg/day b) 40 mg/day c) 60 mg/day d) 80 mg/day | d) >80 mg/day |
SECTION F: SPECIAL POPULATIONS & MONITORING
| # | Question | Options | ✅ Answer |
|---|---|---|---|
| 36 | Most accurate statement regarding TCS in pregnancy: | a) Potent TCS safe in all trimesters b) Mild/moderate preferred; potent → fetal growth retardation c) All TCS absolutely contraindicated d) Superpotent → orofacial cleft | b) Mild/moderate preferred; potent → fetal growth retardation |
| 37 | Why are infants at higher risk for TCS systemic absorption? | a) Thicker stratum corneum b) Higher BSA:body weight ratio + thinner skin c) Higher GC receptor expression d) Increased keratinocyte turnover | b) Higher BSA:weight ratio + thinner skin |
| 38 | When prednisone is 5-10 mg/day, the taper rate (Bologna) should be: | a) 5 mg/week b) 2.5 mg/week c) 1 mg every 2-3 weeks d) 5 mg every 2 weeks | c) 1 mg every 2-3 weeks |
| 39 | Ca + Vit D supplementation should start for systemic GC use of at least: | a) 1 week b) 2 weeks c) 3 months d) 6 months | c) ≥3 months |
| 40 | Live vaccines are safe with systemic GC only at: | a) <5 mg/day any duration b) <10 mg/day c) <20 mg/day (any duration) OR <2 weeks at any dose d) Never safe | c) <20 mg/day any duration OR <2 weeks at any dose |
SECTION G: INTRALESIONAL & SYSTEMIC USE
| # | Question | Options | ✅ Answer |
|---|---|---|---|
| 41 | Initial intralesional triamcinolone concentration for keloids: | a) 2-5 mg/mL b) 5-10 mg/mL c) 10-20 mg/mL d) 20-40 mg/mL | d) 20-40 mg/mL |
| 42 | Monthly limit for intralesional Kenalog to avoid HPA suppression: | a) 10 mg b) 20 mg c) 40 mg d) 80 mg | b) 20 mg/month |
| 43 | Standard IV pulse methylprednisolone dose: | a) 100-250 mg/30 min b) 250-500 mg/1 hour c) 500 mg-1 g over 2 hours d) 2-4 g over 4 hours | c) 500 mg-1 g over 2 hours |
| 44 | IM long-acting triamcinolone acetonide should be given max: | a) 2×/year b) 4-6×/year c) Monthly d) Weekly | b) 4-6 times per year |
| 45 | For cutaneous intralesional injections, preferred formulation is: | a) Triamcinolone hexacetonide b) Triamcinolone diacetate c) Triamcinolone acetonide d) Triamcinolone benetonide | c) Triamcinolone acetonide (NOT hexacetonide) |
SECTION H: CROSS-REACTIVITY & ACD
| # | Question | Options | ✅ Answer |
|---|---|---|---|
| 46 | Budesonide belongs to which cross-reactivity group and cross-reacts with: | a) Group A; cross-reacts with C b) Group B; cross-reacts with D2 c) Group D1; cross-reacts with A d) Group C; cross-reacts with B | b) Group B; cross-reacts with D2 |
| 47 | A patient allergic to hydrocortisone (Group A) — which should you AVOID? | a) Betamethasone dipropionate (D1) b) Methylprednisolone aceponate (D2) → metabolizes to methylprednisolone (A) c) Halcinonide (B) d) Fluticasone propionate (D1) | b) Methylprednisolone aceponate (D2) — metabolizes to Group A |
| 48 | Two most common allergens in TCS vehicles: | a) Parabens and benzyl alcohol b) Propylene glycol and sorbitan sesquioleate c) Cetyl alcohol and polysorbate 80 d) Lanolin and mineral oil | b) Propylene glycol and sorbitan sesquioleate |
SECTION I: PRACTICAL PEARLS & RECENT ADVANCES
| # | Question | Options | ✅ Answer |
|---|---|---|---|
| 49 | The "soak and smear" technique improves TCS penetration because: | a) Removes scale for direct contact b) Stratum corneum hydration ↑ absorption up to 5-fold c) Warm water ↑ systemic blood flow d) Activates GC receptors in epidermis | b) Hydration of stratum corneum → ↑ absorption up to 5-fold |
| 50 | Optimal time for TCS application to maximize vasoconstrictive effect: | a) Early morning b) Midday c) Late afternoon d) Bedtime | c) Late afternoon (endogenous cortisol minimum; TCS peak ~6h post-application) |
| 51 | Which newer steroid-sparing topical was approved post-2020? | a) Pimecrolimus cream b) Tacrolimus ointment c) Ruxolitinib cream 1.5% (JAK1/2 inhibitor) d) Adapalene gel | c) Ruxolitinib cream 1.5% (Opzelura — AD + vitiligo) |
| 52 | Roflumilast cream/foam works by inhibiting: | a) JAK1/2 b) AhR (aryl hydrocarbon receptor) c) PDE4 d) IL-31 receptor | c) PDE4 (phosphodiesterase-4) |
| 53 | Topical steroid withdrawal (TSW) is most commonly reported after: | a) Short-term Class VII TCS use b) Prolonged potent/superpotent TCS on face and genitalia c) Intralesional triamcinolone d) Alternate-day systemic prednisolone | b) Prolonged potent/superpotent TCS — face and genitalia |
| 54 | Which TCS has uniquely low systemic bioavailability due to rapid hepatic first-pass metabolism? | a) Clobetasol propionate b) Triamcinolone acetonide c) Mometasone furoate and fluticasone propionate d) Betamethasone dipropionate | c) Mometasone furoate and fluticasone propionate |
| 55 | Poststeroid panniculitis most commonly occurs in: | a) Adults after prolonged low-dose steroids b) Children after high-dose GC + rapid withdrawal c) Elderly after intralesional injections d) Neonates after topical TCS | b) Children — high-dose GC + rapid withdrawal |
🏆 Scoring Guide
| Score | Level |
|---|---|
| 50-55 | Expert |
| 42-49 | Advanced |
| 30-41 | Proficient |
| <30 | Needs Review |
This is a shared conversation. Sign in to Orris to start your own chat.